Orphan Drug Designation

Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor – Pimicotinib

Researchers in a laboratory working on cancer treatments

2 min read

Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor – Pimicotinib

9 April 2024 (Beijing Time), Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment for its...

First Patient Treated in Phase 2 GvHD Trial

1 min read

First Patient Treated in Phase 2 GvHD Trial

Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that...

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

Mirdametinib Neurofibromatosis Type 1 Treatment

2 min read

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...

The European Commission Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis

NS Pharma NS-229: Orphan Drug Designation for EGPA Treatment

1 min read

The European Commission Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis

NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd, announced today that the European Commission (EC)...

PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

2 min read

PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announces...

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

3 min read

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced it has completed...

Hansa Biopharma Announces Completion of Patient Enrollment in Imlifidase Phase 2 Trial for Guillain-Barré Syndrome

2 min read

Hansa Biopharma Announces Completion of Patient Enrollment in Imlifidase Phase 2 Trial for Guillain-Barré Syndrome

Hansa Biopharma (Nasdaq Stockholm: HNSA), an industry leader in enzyme technology targeting rare immunological conditions, is excited...

Orphan Drug Designation

Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor – Pimicotinib

First Patient Treated in Phase 2 GvHD Trial

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

The European Commission Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis

PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

Hansa Biopharma Announces Completion of Patient Enrollment in Imlifidase Phase 2 Trial for Guillain-Barré Syndrome

You may have missed

IMA to Organize Conference on “Multispecialities Cardio Reno Metabolic & HF in Women” Tomorrow

Justrite® Develops Groundbreaking Solution for the Growing Dangers of Lithium-Ion Battery Fires

Bot Image, Inc. introduced its Prostate Cancer detection, diagnosis, and screening software at urologist meeting in San Antonio, Texas

WS Audiology Strengthens Commitment to Innovation with New R&D Centre of Excellence in Hyderabad